US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Personalis, Inc. - Common Stock
(NQ:
PSNL
)
15.85
+0.03 (+0.19%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Personalis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Investor Notification: Personalis, Inc. ($PSNL) Investors Are Reminded to Contact BFA Law About the Ongoing Investigation into $16.25 per Share Merger Deal
October 24, 2026
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders...
Via
Newsfile
Topics
Artificial Intelligence
PSNL Securities Notice: Personalis, Inc. Shareholders Are Notified to Contact BFA Law About Its Pending Investigation into the $16.25 per Share Merger Deal
October 22, 2026
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders...
Via
Newsfile
Topics
Artificial Intelligence
PSNL Stock Notification: Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced – Investors are Alerted to Contact BFA Law
October 21, 2026
From
Bleichmar Fonti & Auld LLP
Via
Business Wire
Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
October 21, 2026
From
Personalis, Inc.
Via
Business Wire
Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
October 20, 2026
From
Personalis, Inc.
Via
Business Wire
Halper Sadeh LLC is Investigating Whether CSR, FULC, WEAV, PSNL are Obtaining Fair Deals for their Shareholders
September 23, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
September 23, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
September 09, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
September 03, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether UTZ, PSNL, DSGR are Obtaining Fair Deals for their Shareholders
August 07, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Personalis Reports Second Quarter Results and Recent Highlights
August 04, 2026
From
Personalis, Inc.
Via
Business Wire
Halper Sadeh LLC is Investigating Whether UTZ, BLFS, FNWD, PSNL are Obtaining Fair Deals for their Shareholders
July 30, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Shareholders
July 29, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether LXP, FNWD, PSNL are Obtaining Fair Deals for their Shareholders
July 28, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)
July 27, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether UTZ, PSNL, LXP are Obtaining Fair Deals for their Shareholders
July 22, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
July 21, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
July 21, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders
July 20, 2026
From
Halper Sadeh LLC
Via
Business Wire
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
July 20, 2026
From
Personalis, Inc.
Via
Business Wire
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
July 14, 2026
From
Personalis, Inc.
Via
Business Wire
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
June 09, 2026
From
Personalis, Inc.
Via
Business Wire
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
↗
June 04, 2026
This cancer genomics specialist, serving major biopharma and research clients, reported a notable insider sale in its latest SEC filing.
Via
The Motley Fool
Topics
Regulatory Compliance
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
June 02, 2026
From
Personalis, Inc.
Via
Business Wire
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
May 26, 2026
From
Personalis, Inc.
Via
Business Wire
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
May 20, 2026
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate in Upcoming Investor Events
May 14, 2026
From
Personalis, Inc.
Via
Business Wire
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
May 13, 2026
From
Personalis, Inc.
Via
Business Wire
Personalis Q1 Earnings Call Highlights
↗
May 08, 2026
Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business...
Via
MarketBeat
Topics
Earnings
Personalis (PSNL) Q1 2026 Earnings Transcript
↗
May 08, 2026
Personalis (PSNL) Q1 2026 Earnings Transcript
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
